Princeton Junction, NJ, United States of America

Chenkou Wei

This inventor holds 19 USPTO granted patents and 5 published patent applications and 7 EPO patents, primarily in Crystalline Formulations. Top assignees: Bristol-Myers Squibb Compnay, Astrazeneca Ab, Sanofi-Aventis. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chenkou Wei. Retrieved from https://idiyas.com/inventor/chenkou-wei

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 63.2

 

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 111(Granted Patents)


Location History:

  • Princeton, NJ (US) (2012 - 2014)
  • Princeton Junction, NJ (US) (2000 - 2018)

Company Filing History:


Years Active: 2000-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Crystalline Salt Forms
Factor XIa Inhibitor
Imidazole Prodrug
LXR Modulators
Saxagliptin
Triazolopyridine
Hydroxysteroid Dehydrogenase
Spiro-Hydantoin Compounds
Irbesartan
Sonic Impinging Jet
Metformin Salts
Pyridazine Carboxamide
19 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Chenkou Wei

Introduction

Chenkou Wei is a prominent inventor based in Princeton Junction, NJ (US). He holds an impressive portfolio of 18 patents, showcasing his significant contributions to the field of pharmaceutical sciences. His work primarily focuses on developing innovative compounds for treating various medical conditions.

Latest Patents

Among his latest patents, Wei has developed crystalline forms of a factor XIa inhibitor. This invention provides crystalline forms of (S,E)-4-(2-(3-(3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates. The patent also details processes for producing these crystalline forms, pharmaceutical compositions that include them, and methods for treating thromboembolic disorders using these compositions. Another notable patent involves crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline. This invention describes novel compounds used in treating various neurological and physiological disorders.

Career Highlights

Chenkou Wei has had a distinguished career, working with leading pharmaceutical companies such as Bristol-Myers Squibb Company and Sanofi-Synthelabo. His expertise in drug development and innovation has made a significant impact in the pharmaceutical industry.

Collaborations

Throughout his career, Wei has collaborated with notable professionals, including Jack Z Gougoutas and Mary F Malley. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Chenkou Wei's innovative work and numerous patents reflect his dedication to advancing pharmaceutical science. His contributions continue to play a vital role in developing treatments for various medical conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…